Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1990 1
1991 1
1997 1
2000 1
2001 1
2005 2
2006 3
2007 3
2008 1
2009 3
2011 1
2012 3
2013 2
2014 4
2015 5
2016 6
2017 4
2018 6
2019 7
2020 4
2021 3
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Gastric Adenocarcinoma"
Page 1
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. Janjigian YY, et al. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15. J Clin Oncol. 2018. PMID: 30110194 Free PMC article. Clinical Trial.
Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers. We assessed the safety and efficacy of nivolumab and nivolumab plus ipilimumab in Western patients with chemotherapy-refrac …
Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junc …
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, and current guidelines do not recommend any specific treatments for these patients. …
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more …
The treatment landscape for gastroesophageal adenocarcinomas.
Sonbol MB, Pathak S, Bekaii-Saab T. Sonbol MB, et al. Clin Adv Hematol Oncol. 2022 Mar;20(3):169-177. Clin Adv Hematol Oncol. 2022. PMID: 36607347 Review.
The treatment landscape for gastroesophageal adenocarcinomas has significantly changed over the last year. The addition of nivolumab to first-line chemotherapy has led to survival benefit in patients who have metastatic gastroesophageal adenocarcinoma with a program …
The treatment landscape for gastroesophageal adenocarcinomas has significantly changed over the last year. The addition of nivolumab …
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ. Javle M, et al. Oncologist. 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. Oncologist. 2023. PMID: 37390492 Free PMC article. Review.
Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory cancers. Most selective FGFR inhibitors under investigation show reversible binding, and their activity is limited by acquired drug resistance. …
Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory canc …
The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective.
Massironi S, Zilli A, Elvevi A, Invernizzi P. Massironi S, et al. Autoimmun Rev. 2019 Mar;18(3):215-222. doi: 10.1016/j.autrev.2018.08.011. Epub 2019 Jan 11. Autoimmun Rev. 2019. PMID: 30639639 Review.
However, biopsy is the most reliable method to evaluate the presence of metaplastic atrophic gastritis. In order to assess the severity of gastric atrophy and intestinal metaplasia, OLGA and OLGIM staging systems have been proposed and seem to correlate with the risk of de …
However, biopsy is the most reliable method to evaluate the presence of metaplastic atrophic gastritis. In order to assess the severity of …
Helicobacter pylori-Induced Changes in Gastric Acid Secretion and Upper Gastrointestinal Disease.
Smolka AJ, Schubert ML. Smolka AJ, et al. Curr Top Microbiol Immunol. 2017;400:227-252. doi: 10.1007/978-3-319-50520-6_10. Curr Top Microbiol Immunol. 2017. PMID: 28124156 Review.
Acute hypochlorhydria facilitates survival of the bacterium and its infection of the stomach. Interestingly, most patients chronically infected with H. pylori manifest a pangastritis with reduced acid secretion due to bacterial virulence factors, inflammatory cytokines, an …
Acute hypochlorhydria facilitates survival of the bacterium and its infection of the stomach. Interestingly, most patients chronicall …
Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS. Jothimani D, et al. Med Clin North Am. 2023 May;107(3):491-504. doi: 10.1016/j.mcna.2023.01.002. Epub 2023 Feb 20. Med Clin North Am. 2023. PMID: 37001949 Review.
Clinically significant portal hypertension (CSPH) is an important prognostic milestone in patients with liver cirrhosis. This is a pre-symptomatic phase that predicts the development of varices, ascites and importantly increased risk of Hepatocellular carcinoma (HCC). ...P …
Clinically significant portal hypertension (CSPH) is an important prognostic milestone in patients with liver cirrhosis. This is a pre-sympt …
Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H, Liu X, Jiang L, Li F, Zhang R, Wang P. Song H, et al. Recent Pat Anticancer Drug Discov. 2021;16(3):312-332. doi: 10.2174/1574892816666210208231744. Recent Pat Anticancer Drug Discov. 2021. PMID: 33563158 Review.
Currently, camrelizumab is undergoing clinical research for advanced solid tumors such as liver cancer, gastric cancer, esophageal cancer, and lung cancer, and all have shown clinical efficacy. ...The incidence of adverse reactions with camrelizumab is low, with most being …
Currently, camrelizumab is undergoing clinical research for advanced solid tumors such as liver cancer, gastric cancer, esophageal ca …
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.
Saeed A, Park R, Dai J, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Saeed A, Ripp J, Collins Z, Mulvaney K, Shugrue M, Firth-Braun J, Godwin AK, Madan R, Phadnis M, Sun W. Saeed A, et al. Cell Rep Med. 2023 Feb 21;4(2):100916. doi: 10.1016/j.xcrm.2023.100916. Epub 2023 Jan 25. Cell Rep Med. 2023. PMID: 36702123 Free PMC article. Clinical Trial.
This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable (pMMR/MSS) gastrointestinal malignancies including gastric/gastroesophageal junction/es …
This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus durvalumab in advanced chemo-refractory profic …
Laparoscopic total esophagectomy.
Swanstrom LL, Hansen P. Swanstrom LL, et al. Arch Surg. 1997 Sep;132(9):943-7; discussion 947-9. doi: 10.1001/archsurg.1997.01430330009001. Arch Surg. 1997. PMID: 9301605
PATIENTS: Between December 12, 1993, and December 1, 1996, 9 patients with a mean age of 61 years underwent laparoscopic esophagectomy. Indications were adenocarcinoma in 5, squamous cell carcinoma in 1, dysplastic Barrett esophagus in 2, and refractory stricture wi …
PATIENTS: Between December 12, 1993, and December 1, 1996, 9 patients with a mean age of 61 years underwent laparoscopic esophagectomy. Indi …
64 results